Researchers Find Targeted Vaccination Of Women Of Reproductive Age Is ‘Noteworthy’ Measure For Mitigating Effects Of Zika

CDC’s “Emerging Infectious Diseases”: Cost-effectiveness of Prophylactic Zika Virus Vaccine in the Americas
Affan Shoukat, with York University in Toronto and a postdoctoral fellow at Yale University, and colleagues assessed the cost-effectiveness of a prophylactic vaccine for Zika, finding “targeted vaccination of women of reproductive age is a noteworthy preventive measure for mitigating the effects of Zika virus infection in future outbreaks” (December 2019).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.